A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

What Was Tested

Researchers studied Thymosin Beta-4 (full length) in this randomized controlled trial publication.

Synthetic thymosin beta 4 (Tbeta4) may have a potential use in promoting myocardial cell survival during acute myocardial infarction.

Adverse events were infrequent, and mild or moderate in intensity.

Who Took Part

The abstract describes 10 subjects taking part.

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Thymosin Beta-4 (full length) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Thymosin Beta-4 (full length).

Some subjects received a placebo instead of Thymosin Beta-4 (full length), giving a reference point.

The methods mention a period of 14 days.

What Was Measured

Topics PubMed links to this paper include Clinical Protocols, Cohort Studies, Half-Life, Thymosin and Thymosin beta(4).

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Thymosin Beta-4 (full length) in 10 subjects over 14 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2010 (Annals of the New York Academy of Sciences), a journal based in United States.

More context: the Thymosin Beta-4 (full length) compound page, all human trials.